FIL Ltd bought a new position in Iovance Biotherapeutics Inc (NASDAQ:IOVA) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 1,336,179 shares of the biotechnology company’s stock, valued at approximately $15,032,000. FIL Ltd owned 1.40% of Iovance Biotherapeutics at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently made changes to their positions in the business. Amalgamated Bank bought a new stake in Iovance Biotherapeutics during the second quarter valued at about $161,000. Creative Planning raised its holdings in Iovance Biotherapeutics by 70.8% during the second quarter. Creative Planning now owns 19,650 shares of the biotechnology company’s stock valued at $252,000 after acquiring an additional 8,145 shares during the period. TD Asset Management Inc. raised its holdings in Iovance Biotherapeutics by 29.3% during the second quarter. TD Asset Management Inc. now owns 98,800 shares of the biotechnology company’s stock valued at $1,265,000 after acquiring an additional 22,400 shares during the period. Suffolk Capital Management LLC raised its holdings in Iovance Biotherapeutics by 20.6% during the second quarter. Suffolk Capital Management LLC now owns 37,827 shares of the biotechnology company’s stock valued at $484,000 after acquiring an additional 6,456 shares during the period. Finally, Victory Capital Management Inc. raised its holdings in Iovance Biotherapeutics by 2.6% during the second quarter. Victory Capital Management Inc. now owns 2,344,279 shares of the biotechnology company’s stock valued at $30,007,000 after acquiring an additional 58,780 shares during the period. Institutional investors own 92.83% of the company’s stock.
Shares of IOVA stock opened at $9.15 on Friday. Iovance Biotherapeutics Inc has a 12-month low of $7.85 and a 12-month high of $19.90.
Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.03). As a group, analysts predict that Iovance Biotherapeutics Inc will post -1.24 EPS for the current year.
A number of research firms have commented on IOVA. HC Wainwright set a $22.00 price target on Iovance Biotherapeutics and gave the company a “buy” rating in a report on Thursday, September 6th. BidaskClub cut Iovance Biotherapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 28th. Zacks Investment Research raised Iovance Biotherapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Wednesday, October 17th. Citigroup raised their price target on Iovance Biotherapeutics from $22.00 to $25.00 and gave the company an “outperform” rating in a report on Friday, October 12th. Finally, ValuEngine cut Iovance Biotherapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 6th. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. Iovance Biotherapeutics presently has an average rating of “Buy” and a consensus price target of $23.75.
ILLEGAL ACTIVITY WARNING: “1,336,179 Shares in Iovance Biotherapeutics Inc (IOVA) Acquired by FIL Ltd” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/11/30/1336179-shares-in-iovance-biotherapeutics-inc-iova-acquired-by-fil-ltd.html.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.
Further Reading: What is a conference call?
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.